 The primary objectives of the study are to test whether brain Mono Amine Oxidase-A MAO-A levels are elevated in patients with treatment-resistant major depression, and to explore whether MAO-A brain levels predict treatment outcome with Mono Amine Oxidase Inhibitor MAOI medication in this population. 